2023 Fiscal Year Final Research Report
Involvement of the TRX/TXNIP antioxidant and glycation system in the brain in the pathophysiology of schizophrenia
| Project/Area Number |
19K17075
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 52030:Psychiatry-related
|
|---|
| Research Institution | Juntendo University (2021, 2023)
Tokyo Metropolitan Institute of Medical Science (2019-2020) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2024-03-31
|
| Keywords | 統合失調症 / 個別化医療 / 層別化 / 遺伝要因 / 抗糖化 / 抗酸化 / チオレドキシン |
|---|
| Outline of Final Research Achievements |
In schizophrenia patients with enhanced advanced glycation end product, we found the possible involvement of the deletion of TXNIP gene located within the 1q21.1. We also performed the re-sequencing of the TXNIP gene of the "Thioredoxin/TXNIP system," an intrinsic mechanism against glycation stress and oxidative stress in the brain. We identified c.224 C/T (Thr 75 Met), which is accompanied by an amino acid substitution, only in the patient group. In silico analysis suggested that this mutation may have damaging effect. We also identified various potentially functional variants located at the 3'UTR binding region of the microRNA.
|
| Free Research Field |
精神医学
|
| Academic Significance and Societal Importance of the Research Achievements |
統合失調症においても、他の診療科と同様に、病態ごとに層別化された集団に対し、ゲノム情報をもとにした個別化医療の進展が待たれている。本研究においては、終末糖化産物の蓄積という中間表現型を呈する統合失調症に注目し、その遺伝要因として1q21.1欠失というコピー数多型の関与を提示し、さらに同欠失内に含まれる内因性抗糖化・酸化システムを担うTXNIP遺伝子におけるdamagingな変異を患者群で報告したことが学術的な意義があると考えている。今後、統合失調症の個別化医療を実装する際のゲノム基盤の一つを提示したという観点からは、社会的要請にこたえる研究成果であると考えている。
|
